Sunday, July 4, 2021

WHO grants Sinopharm’s COVID-19 vaccine emergency approval

The World Health Organization (WHO) has approved Sinopharm’s COVID-19 vaccine for emergency use, making it the first jab developed by a non-Western company to gain this recommendation.

So far, the WHO has approved vaccines from Pfizer/BioNTech, AstraZeneca/Oxford University, Johnson & Johnson (J&J) and Moderna.

“This expands the list of COVID-19 vaccines that COVAX can buy, and gives countries confidence to expedite their own regulatory approval, and to import and administer a vaccine,” said Tedros Adhanom Ghebreyesus, director-general of the WHO.

A WHO emergency use listing (EUL) was granted following an assessment by a technical advisory group (TAG), which assesses the quality, safety and efficacy of COVID-19 vaccines.

Sinopharm’s vaccine is an inactivated vaccine, with ‘easy’ storage requirements that make it suitable for low-resource settings, the WHO said in a statement.

The vaccine has an efficacy of 79% against symptomatic and hospitalised COVID-19 disease across all age groups – the WHO approved the jab for use in adults aged 18 years and older on the basis of this evidence.

However, the WHO added that as a result of small numbers of older adults having been enrolled in clinical trials, efficacy could not be estimated in this age group.

Even still, WHO is not recommending an upper age limit for the Sinopharm vaccine as preliminary data and supportive immunogenicity data suggest the vaccine is ‘likely’ to have some sort of protective effect in people aged 60 years and older.

In addition to signalling the safety and efficacy of a vaccine, a WHO EUL is also a prerequisite for the COVAX Facility vaccine sharing mechanism.

“The addition of this vaccine has the potential to rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk,” said Mariângela Simão, WHO assistant-director general for access to health products.

“We urge the manufacturer to participate in the COVAX Facility and contribute to the goal of more equitable vaccine distribution,” she added.

Source link

Stay Connected


Latest Articles

Covid’s second wave proves lethal for pregnant women

At SVP Hospital in Ahmedabad – one of the major Covid-19 hospitals of the city – 148 pregnant women with Covid-19 infection were admitted...

7 Tips to Keep Your Gut Healthy

This is common to say health (and illness) starts in your gut. If you have poor gut health, you’ll experience anything from wrinkled skin, to...

SII making first batch of Covovax: Poonawalla

The first batch of Covovax, a Covid-19 vaccine developed by Novavax Inc, is being manufactured at the Serum Institute of India's Pune facility, SII...

Sputnik V is safest among all Covid-19 vaccines, no deaths recorded: Buenos Aires study

A study by the Buenos Aires Ministry of Health to monitor the safety of the Sputnik V vaccine against Covid-19 confirmed on Thursday that...

Telangana caps Covid treatment charges in private hospitals

Hyderabad: The government of Telangana on Wednesday issued orders fixing treatment and investigation charges for Covid-19 in private hospitals.The state government, which had capped...